Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
evorpacept + rituximab + lenalidomide
- Development stage
- Phase 2
- Lead developer
- ALX Oncology
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Evorpacept (ALX148) is a high-affinity signal regulatory protein alpha (SIRPα) fusion protein designed to block the CD47 checkpoint on cancer cells, thereby neutralizing the 'do-not-eat-me' signal and enabling macrophage-mediated phagocytosis. In this specific clinical context at M.D. Anderson Cancer Center, evorpacept is being evaluated in an investigator-initiated Phase I/II trial (NCT05025800) in combination with rituximab, a CD20-targeting monoclonal antibody, and lenalidomide, an immunomodulatory imide drug (IMiD). This triplet combination therapy is intended to treat patients with various subtypes of B-cell non-Hodgkin lymphoma, including follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma, by leveraging the synergistic effects of CD47 blockade, antibody-dependent cellular cytotoxicity (ADCC), and immunomodulation to enhance anti-tumor immune responses.
- Other names
- ALX148 + Rituximab + LenalidomideCD47 Antagonist ALX148 + Rituximab + Lenalidomide
02
Targets
CD20 (B-lymphocyte antigen CD20)CD47 (Cluster of Differentiation 47)CRBN (Cereblon)SIRPA (Signal-regulatory protein alpha)
Beyond the preview
Go deeper on evorpacept + rituximab + lenalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on evorpacept + rituximab + lenalidomide.